[{"id":"836f4bce-9009-4914-929c-c6bb7d4697d9","acronym":"NCI-2019-06910","url":"https://clinicaltrials.gov/study/NCT03459859","created_at":"2022-10-04T15:55:39.371Z","updated_at":"2025-02-25T14:50:55.754Z","phase":"Phase 1","brief_title":"Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS","source_id_and_acronym":"NCT03459859 - NCI-2019-06910","lead_sponsor":"Justin Watts, MD","biomarkers":" CDT1","pipe":"","alterations":" ","tags":["CDT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • pevonedistat (MLN4924)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 05/21/2018","start_date":" 05/21/2018","primary_txt":" Primary completion: 06/25/2021","primary_completion_date":" 06/25/2021","study_txt":" Completion: 06/25/2021","study_completion_date":" 06/25/2021","last_update_posted":"2021-12-28"}]